

## PRESS RELEASE

## Medisan Pharmaceuticals changes its name to BioPhausia

At the General Shareholders Meeting on May 21st it was decided that Medisan Pharmaceuticals will change its name to BioPhausia. The new name will be used to identify the company on the SBI stock list in Stockholm from Monday June 2nd.

The change of name to BioPhausia reflects the company's increased emphasis on Research and Development, now of dominating importance for future growth and profitability.

Stellan Lind, President and CEO says: "The change of name is in line with our increased committment to Research and Development. We want to communicate the new direction of the company and facilitate the understanding of our mission among investors and within the industry".

Based on its know-how and contact network primarily in connective tissue biology, **BioPhausia** develops pharmaceuticals with well defined clinical and pharmaeconomic advantages.

BioPhausia's project portfolio includes the small volume resuscitation solution RescueFlow® presently in FDA regulatory assessment phase, Krillase<sup>TM</sup> for debridement of chronic ulcers in phase III clinical trials and preclinical projects in the areas of surgical pharmacotherapy and tumour treatment.

Uppsala, Sweden, May 28th, 1997.

For further information please contact: Stellan Lind, President and CEO or Richard Hainsworth Vice President and COO at the address below.